Husna, Amity University Kolkata
Oncolytic viruses are genetically engineered for the destruction of cancer or tumour-causing cells specifically. They’re delivered for treatment inside the body via intravenous injection. In 2015, one such oncolytic virus was approved by the FDA for treating skin cancer, melanoma. A major obstacle in the application of oncolytic adenoviruses is that they face a barrier from the human immune system. The antibodies and blood components neutralize the injected adenovirus doses and also send it to the liver, the body’s garbage disposal. Some patients also developed inflammation and infection reaction on the application of oncolytic adenovirus.
Recently these barriers have been overcome by the researchers from the Pharmacology department of Case Western Reserve University. They’ve re-engineered the human adenovirus in such a way that it doesn’t get caught by parts of the innate immune system easily. Dmitry Shayakhmetov, PhD has stated that now it is possible to deliver the modified virus systemically at possible high doses for suppression of the tumour growth and even the life-threatening systemic toxicities or inflammatory reaction won’t get triggered anymore. Furthermore, the re-engineered adenoviruses can be armed with genes and proteins that can stimulate an immunity to cancer.
The re-engineered adenovirus is therefore a technology which can be customized for various cancer patients and can be used as personalized life-saving therapy to patients with metastatic cancer.
Also read:None of the SARS-CoV-2 Genetic Mutations Appear to Increase Transmissibility
SOURCE:
https://scitechdaily.com/new-weapon-against-metastatic-cancer-engineered-stealth-bomber-virus/
Very well written. Illuminating content.
👍well written
As Iam very much interested in cancer biology, I personally like this article and its written in a very comprehensible manner.